Behavioral Health

ADHD in adults: diagnosis and pharmacotherapy

Clinical Overview and When to Suspect Adult ADHD

— Prevalence in US adults ~4.4% (NCS-R); only ~20% receive treatment

— 2:1 male predominance in childhood narrows to ~1.5:1 in adults; women are underdiagnosed (more inattentive presentation)

— ~60% of childhood ADHD persists into adulthood in some form; pure adult-onset is rare and should prompt scrutiny for mimics

— ≥5 (not 6) symptoms of inattention and/or hyperactivity-impulsivity for ≥6 months

— Several symptoms present before age 12 (this is the critical developmental anchor)

— Impairment in ≥2 settings, not better explained by another disorder

— Chronic procrastination, missed deadlines, job-hopping, financial disorganization

— Driving violations, traffic accidents (ADHD doubles MVC risk)

— Comorbid anxiety, depression, or substance use that responds incompletely to first-line treatment

— Relationship strain attributed to "forgetfulness" or "not listening"

— Family history of ADHD (heritability ~75%)

Board pearl: Adult-onset symptoms without any childhood history should redirect the differential toward mood disorder, substance use, thyroid disease, sleep apnea, or early dementia — not ADHD. The pre-age-12 onset rule is the single most tested diagnostic anchor.

Step 3 management: Initial outpatient encounter focuses on a structured interview using DSM-5-TR criteria plus collateral history; rating scales support but never replace the clinical interview.

Definition: Neurodevelopmental disorder characterized by persistent inattention and/or hyperactivity-impulsivity causing functional impairment across ≥2 settings (work, home, relationships, academics).

Epidemiology:

Core DSM-5-TR criteria for adults:

When to suspect in clinic:

Common Step 3 vignette setup: 28-year-old graduate student or new professional with declining performance despite intact intelligence, multiple unfinished projects, losing keys/phone, interrupting others, and a childhood history of being "the class clown" or "daydreamer."

Presentation Patterns and Key History

— Careless errors on spreadsheets, emails, tax forms

— Difficulty sustaining attention in meetings or while reading

— Appears not to listen; loses items (wallet, phone, badge)

— Easily distracted by extraneous stimuli or intrusive thoughts

— Forgetful in daily routines (bills, appointments, medication adherence)

— Avoids tasks requiring sustained mental effort

— Internal restlessness more than overt motor hyperactivity

— Fidgeting, tapping, inability to sit through long meetings

— Excessive talking, blurting answers, finishing others' sentences

— Difficulty waiting turn (in traffic, lines, conversations)

— Impulsive spending, job changes, relationship decisions

— Predominantly inattentive (most common in adult women)

— Predominantly hyperactive-impulsive (rare in adults)

— Combined

— School records, report cards ("doesn't apply herself," "talks too much")

— Driving record, employment timeline, academic accommodations history

— Sleep schedule (rule out insufficient sleep, OSA)

— Substance use including caffeine, nicotine, cannabis, stimulants

— Screen for comorbidities: MDD, GAD, bipolar disorder, SUD, learning disability, autism spectrum

— ASRS v1.1 (Adult ADHD Self-Report Scale) — 6-item screener, sensitivity ~69%, specificity ~99%

— Conners' Adult ADHD Rating Scale, WURS (childhood retrospective)

— Collateral informant report (partner, parent) increases diagnostic confidence

Key distinction: Inattention from major depression is episodic and mood-congruent; ADHD inattention is lifelong and trait-like. Bipolar distractibility occurs during discrete manic/hypomanic episodes with elevated mood and decreased sleep need — ADHD lacks the episodicity.

Board pearl: Ask about "hyperfocus" — the paradoxical ability to lock into stimulating tasks (video games, art) for hours. It supports rather than excludes ADHD because attention is dysregulated, not absent.

Inattentive symptoms (adult flavor):

Hyperactive-impulsive symptoms (adult flavor):

Three DSM-5-TR presentations:

High-yield history elements to elicit:

Validated screening tools:

Physical Exam Findings and Baseline Cardiovascular Assessment

— Often unremarkable; may note fidgeting, leg-jiggling, interrupting examiner, shifting topics

— Mental status: intact cognition, normal thought process despite tangential flow; mood euthymic unless comorbid

— No focal neurologic deficits — their presence should prompt alternative workup

— Resting heart rate and blood pressure in both arms

— Auscultation for murmurs (HCM, valvular disease)

— Peripheral pulses, signs of heart failure

— Document baseline weight, height, BMI

— Syncope, exertional chest pain, palpitations

— Family history of sudden cardiac death <40, HCM, long QT, arrhythmogenic cardiomyopathy

— Known structural heart disease, uncontrolled hypertension (>140/90), tachyarrhythmia

— Marfanoid habitus, pectus excavatum (consider HCM/aortopathy)

— Tics (Tourette's comorbidity — stimulants may unmask but rarely cause)

— Tremor (baseline before stimulant)

— Signs of hyperthyroidism: tachycardia, tremor, lid lag, goiter

— Nasal septal changes (cocaine), needle marks, alcohol stigmata

— These shape both differential and treatment safety

Step 3 management: Routine ECG before stimulant initiation is NOT recommended in asymptomatic adults without cardiac risk factors (AHA/AAP joint statement). Obtain ECG only if history, family history, or exam suggests structural or electrical heart disease. This is a frequently tested distractor.

Board pearl: A vignette featuring an adult with ADHD symptoms plus exertional syncope and a systolic murmur that increases with Valsalva should trigger an echocardiogram for HCM before any stimulant — never start methylphenidate first.

Key distinction: Baseline BP/HR documentation is required at every visit; ECG is selective. Memorize this asymmetry — it shows up on exams.

General psychiatric exam:

Cardiovascular exam (mandatory before stimulant therapy):

Red flags on exam or history that delay stimulant initiation:

Neurologic screen:

Substance use exam clues:

Diagnostic Workup — Initial Labs and Rule-Out Studies

— TSH if any features of thyroid disease (weight change, heat/cold intolerance, tachycardia)

— CBC if fatigue or pallor (anemia mimics inattention)

— CMP including glucose, LFTs (baseline before pharmacotherapy)

— Vitamin B12, ferritin if dietary risk, fatigue, or restless legs

— Urine toxicology when substance use is suspected or stimulant prescribing is planned — many practices document baseline UDS as standard of care

— HIV/syphilis if cognitive complaints are recent-onset in at-risk patient

— Screen all patients with Epworth Sleepiness Scale or STOP-BANG

— Polysomnography if OSA suspected (obesity, snoring, witnessed apneas, AM headaches) — untreated OSA mimics inattentive ADHD and worsens with stimulants

— Not required for diagnosis

— Useful when learning disability, TBI, or cognitive disorder is suspected, or when school/work accommodations require documentation

— Continuous Performance Tests (CPT, TOVA) have poor specificity — normal results do not exclude ADHD

— Not indicated routinely

— Obtain MRI if focal neurologic findings, atypical course, or new-onset cognitive decline

Board pearl: A 35-year-old with new "concentration problems," daytime sleepiness, BMI 38, and loud snoring needs a sleep study before an ADHD workup — treating presumed ADHD with stimulants in untreated OSA worsens cardiovascular risk and rarely improves symptoms.

Step 3 management: Document a negative pregnancy test, baseline vitals, BMI, and a targeted symptom rating scale (ASRS) in the chart before prescribing controlled substances — this is both clinically sound and medicolegally protective.

ADHD is a clinical diagnosis — no lab, imaging, or neuropsychological test confirms it. Workup targets mimics and comorbidities.

Recommended baseline labs (selective, not universal):

Sleep evaluation:

Pregnancy testing in patients of childbearing potential before initiating stimulants or atomoxetine

Neuropsychological testing:

EEG and neuroimaging:

Diagnostic Workup — Confirmatory Assessment and Comorbidity Mapping

— DIVA-5 (Diagnostic Interview for ADHD in adults) — symptom-by-symptom DSM walk-through

— Conners' Adult ADHD Diagnostic Interview (CAADID)

— Both anchor adult symptoms to childhood onset and functional impairment

— DSM-5-TR symptom count (≥5 in inattention and/or hyperactivity-impulsivity)

— Onset of several symptoms before age 12 (parent/sibling collateral or school records strengthen this)

— Impairment in ≥2 domains

— Symptoms not better explained by another disorder

— Quantitative baseline (ASRS, Adult ADHD Investigator Symptom Rating Scale — AISRS)

— Major depressive disorder (~20-30%)

— Anxiety disorders (~25-50%)

— Substance use disorder (~15-25%, especially alcohol, cannabis, stimulants)

— Bipolar disorder (~5-10%) — must be screened with MDQ before stimulants

— Learning disabilities, autism spectrum, personality disorders (especially borderline)

— Insomnia and delayed sleep phase syndrome

— Stabilize bipolar disorder, active SUD, severe depression, or psychosis FIRST

— Treat ADHD once comorbid condition is controlled or in partial remission

— Untreated bipolar disorder + stimulant = manic switch risk

Key distinction: Borderline personality disorder features affective instability triggered by interpersonal stress and identity disturbance; ADHD impulsivity is stimulus-driven and lacks the abandonment/identity core. They frequently co-occur and require sequential, not simultaneous, treatment focus.

Board pearl: Always administer the MDQ (Mood Disorder Questionnaire) before prescribing stimulants. A positive screen mandates a deeper bipolar workup — missing bipolar II and prescribing amphetamines is a classic exam trap and a real-world harm.

Step 3 management: Coordinate care: notify the patient's PCP and any mental health prescriber when starting a controlled substance, and check the state PDMP at every refill.

Structured clinical interview is the gold standard:

Documentation requirements before pharmacotherapy:

Comorbidity is the rule, not the exception (~70-80% of adults with ADHD):

Sequencing principle:

Treatment Framework and First-Line Management Logic

— Stimulants (methylphenidate or amphetamine class) have effect sizes ~0.8-1.0

— Non-stimulants (atomoxetine, viloxazine, α2-agonists) effect sizes ~0.4-0.7

— Either methylphenidate or amphetamine is acceptable first-line; ~70% respond to any given stimulant, ~85-90% respond to one of the two classes after a sequential trial

— Long-acting formulations preferred for adherence, smoother coverage, and lower diversion/abuse potential

— Active or recent substance use disorder (atomoxetine first-line)

— Significant anxiety where stimulants worsen symptoms

— Tic disorder (relative, not absolute, contraindication to stimulants)

— Patient preference or occupation requiring no controlled substance (commercial pilots, some military roles)

— Cardiovascular concerns where stimulant risk outweighs benefit

— Cognitive-behavioral therapy adapted for ADHD (organization, time management, emotion regulation)

— ADHD coaching, environmental modification, sleep hygiene

— Workplace accommodations under ADA (extended deadlines, quiet workspace)

— Re-assess at 2-4 weeks after initiation/titration, then every 3 months once stable, then every 6 months

Step 3 management: Document a stimulant treatment agreement (single prescriber, single pharmacy, no early refills, PDMP review, urine drug screen as clinically indicated). This is increasingly tested as part of safe controlled-substance prescribing.

Board pearl: The single most evidence-supported intervention for adult ADHD is stimulant + CBT, outperforming either alone for functional outcomes.

Treatment goal: Functional improvement (work, relationships, safety) — not symptom eradication. Use measurement-based care with serial ASRS or AISRS.

First-line treatment in uncomplicated adult ADHD: stimulant monotherapy + psychoeducation/behavioral strategies.

Choosing stimulant class:

When to prefer a non-stimulant first-line:

Behavioral and psychosocial adjuncts (always recommended):

Measurement-based follow-up cadence:

Pharmacotherapy — Stimulants in Depth

— Short-acting: methylphenidate IR (Ritalin) — 5-20 mg BID-TID, duration 3-4 h

— Intermediate: Ritalin LA, Metadate CD — 8 h

— Long-acting: Concerta (OROS, 10-12 h), Jornay PM (evening-dosed, AM onset), Daytrana patch

— d-methylphenidate (Focalin, Focalin XR) — twice as potent per mg

— Typical adult target: 0.5-1 mg/kg/day, max ~72 mg/day (Concerta) or 60 mg/day (Focalin XR)

— Mixed amphetamine salts: Adderall IR (4-6 h), Adderall XR (10-12 h)

— Lisdexamfetamine (Vyvanse): prodrug, 12-14 h, lower abuse potential (must be hydrolyzed by RBC enzymes — cannot be snorted or injected effectively)

— d-amphetamine (Dexedrine, Zenzedi)

— Typical adult target: 0.3-0.7 mg/kg/day; lisdexamfetamine 30-70 mg daily

— Start low, titrate every 3-7 days based on response and tolerability

— Re-evaluate BP, HR, weight, sleep, appetite at each visit

— Decreased appetite, weight loss, insomnia, dry mouth, headache, jitteriness

— Mild BP/HR elevation (~3-5 mmHg, ~3-6 bpm)

— Emotional blunting at high doses

— New-onset psychosis or mania (~0.1%)

— Priapism (rare, methylphenidate)

— Raynaud phenomenon, peripheral vasculopathy

— Sudden cardiac death in patients with structural heart disease

Board pearl: Lisdexamfetamine is preferred when diversion or misuse risk is a concern — the prodrug design makes it tamper-resistant.

CCS pearl: When titrating, advance the order set with "BP, HR, weight" at each follow-up and order PDMP query before refills.

Methylphenidate class (blocks DAT and NET):

Amphetamine class (releases DA/NE from vesicles, weak reuptake inhibitor):

Initiation and titration:

Common adverse effects:

Serious/uncommon:

Contraindications: Symptomatic CV disease, uncontrolled HTN, hyperthyroidism, glaucoma, MAOI within 14 days, current stimulant use disorder

Pharmacotherapy — Non-Stimulants and Combination Strategies

— Dose: start 40 mg/day, target 80-100 mg/day (1.2 mg/kg)

— Onset of effect: 2-6 weeks (slower than stimulants)

— First-line non-stimulant; preferred when comorbid SUD, anxiety, or tic disorder

— Adverse effects: nausea, dry mouth, decreased appetite, sexual dysfunction, fatigue, mild BP/HR elevation

— Black box: suicidal ideation in young adults; hepatotoxicity (rare) — counsel on jaundice/RUQ pain

— CYP2D6 substrate — reduce dose in poor metabolizers or with fluoxetine/paroxetine

— FDA-approved for adults 2022; 200-600 mg/day

— Similar profile to atomoxetine, also carries suicidality warning

— CYP1A2 inhibitor — avoid with theophylline, tizanidine

— Guanfacine ER (Intuniv), clonidine ER (Kapvay) — FDA-approved in children/adolescents; used off-label in adults, often adjunctive

— Useful for hyperarousal, sleep onset, emotional dysregulation

— Watch hypotension, bradycardia, sedation; taper to avoid rebound HTN

— Reasonable when comorbid depression, tobacco use disorder, or stimulant intolerance

— Lowers seizure threshold; avoid in eating disorders, seizure history

— Stimulant + atomoxetine for partial responders

— Stimulant + α2-agonist for residual hyperarousal/insomnia

— Avoid combining two stimulants of the same class

— Failure of methylphenidate at adequate dose/duration → trial amphetamine (and vice versa) before declaring stimulant failure

— True stimulant non-response → atomoxetine or viloxazine

Key distinction: Stimulants give same-day response; non-stimulants require weeks. Counsel patients explicitly to prevent premature discontinuation of atomoxetine.

Step 3 management: For a patient with ADHD + active alcohol use disorder, start atomoxetine and refer to SUD treatment simultaneously — do not wait for sobriety before treating ADHD, as untreated ADHD worsens relapse risk.

Atomoxetine (Strattera): Selective NET inhibitor

Viloxazine ER (Qelbree): NET inhibitor + serotonergic activity

α2-adrenergic agonists:

Bupropion (off-label):

Combination therapy:

Switching strategies:

Special Populations — Elderly and Renal/Hepatic Impairment

— ADHD persists into later life; prevalence ~3% in adults >60

— New diagnosis after age 50 is uncommon — rule out MCI, early dementia, depression, OSA, medication effects, hearing/visual decline first

— Cognitive testing (MoCA) helps distinguish age-related cognitive decline from ADHD

— Higher baseline rates of HTN, CAD, atrial fibrillation

— Obtain ECG and consider echocardiogram before stimulant if any cardiac history

— Use lower starting doses (e.g., methylphenidate 2.5-5 mg BID; lisdexamfetamine 20 mg)

— Monitor BP/HR closely; orthostatic vitals if α2-agonist used

— Consider atomoxetine if CV risk is high

— Methylphenidate: minimal renal clearance; generally safe, no dose adjustment

— Amphetamines: renal excretion; reduce dose in CrCl <30; avoid in ESRD

— Lisdexamfetamine: max 50 mg/day if eGFR 15-30; max 30 mg/day if ESRD

— Atomoxetine: no adjustment needed in renal impairment

— Guanfacine: consider dose reduction in severe renal disease

— Atomoxetine: reduce dose 50% in Child-Pugh B, 75% in Child-Pugh C

— Viloxazine: caution; limited data

— Stimulants: generally hepatically metabolized but no formal adjustment; monitor LFTs if baseline elevated

— Stimulants + SSRIs/SNRIs → additive serotonergic and sympathomimetic effects; serotonin syndrome rare but reported

— Stimulants + MAOIs (including linezolid, methylene blue) → hypertensive crisis — absolute contraindication, 14-day washout

— Atomoxetine + strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) → reduce dose by 50-75%

Board pearl: New cognitive complaints in a 68-year-old with no childhood history is dementia or depression workup, not an ADHD trial. The pre-age-12 anchor protects you.

Step 3 management: In any adult >50 starting a stimulant, document BP, HR, ECG review, and a shared-decision conversation about CV risk in the chart.

Older adults (>55) with ADHD:

Cardiovascular caution in elderly:

Renal impairment:

Hepatic impairment:

Polypharmacy interactions:

Special Populations — Pregnancy, Lactation, and College/Transition-Age Patients

— All ADHD medications cross the placenta to some degree

— Stimulants in pregnancy: Associated with small increased risks of preeclampsia, preterm birth, low birth weight; teratogenicity signal weak/inconsistent

— Methylphenidate has more reassuring data than amphetamines

— Shared decision-making: continue if functional impairment without treatment poses greater risk (e.g., driving safety, employment loss, severe disorganization affecting prenatal care)

— Many patients taper before conception or in first trimester if symptoms are mild-moderate

— Atomoxetine: limited human data; not first-choice in pregnancy

— Avoid bupropion in 1st trimester (cardiac malformation signal — weak)

— Stimulants enter breast milk in small amounts; methylphenidate has the most reassuring data

— Monitor infant for irritability, poor feeding, sleep disturbance

— Atomoxetine: limited data; generally avoided

— Document effective contraception before stimulant or atomoxetine initiation in patients of childbearing potential

— High risk of diversion and misuse — up to 20% of college students with stimulant prescriptions divert

— Prefer lisdexamfetamine or long-acting formulations

— Single-pharmacy rule, no early refills, signed treatment agreement

— Screen for SUD at every visit (AUDIT-C, DAST)

— Coordinate with student health and provide PDMP-verified prescriptions

— Pediatric-to-adult handoff is a high-risk gap — ~50% of young adults lose treatment continuity

— Provide a written transition plan, warm handoff to adult prescriber, and 90-day overlap

Board pearl: Diversion question — a college student requests early refills citing "lost pills." Correct response: verify PDMP, do NOT refill early, schedule visit, consider switching to lisdexamfetamine, and reinforce treatment agreement.

Step 3 management: In pregnancy, coordinate with OB and psychiatry — never unilaterally discontinue or continue without multidisciplinary input.

Pregnancy:

Lactation:

Contraception counseling:

College and transition-age adults (18-25):

Transitions of care:

Complications and Adverse Outcomes

— Lower educational attainment, unemployment, lower income

— 2-4× higher motor vehicle accident rate

— Higher rates of substance use disorder (especially nicotine, cannabis, alcohol)

— Increased suicide attempts and completed suicide (independent of comorbid depression)

— Relationship instability, divorce

— Higher all-cause mortality (Danish cohort: HR ~2.0)

— Cardiovascular: modest BP/HR increase; sudden cardiac death rare and primarily in patients with structural heart disease; small absolute risk of MI/stroke in adults with cardiac risk factors

— Psychiatric: new-onset psychosis or mania (~0.1%), worsened anxiety, emotional blunting, irritability during washout ("rebound")

— Sleep: insomnia, especially with afternoon dosing

— Appetite/weight: decreased appetite, weight loss (monitor BMI)

— Misuse and dependence: moderate risk; lower with prodrugs and long-acting formulations

— Stimulant use disorder: especially with IR formulations, non-oral routes

— Tics: unmask or worsen in predisposed patients

— Priapism, peripheral vasculopathy (Raynaud-like) — uncommon but tested

— Suicidal ideation (black box, especially young adults)

— Hepatotoxicity (rare, idiosyncratic) — stop with jaundice, dark urine, RUQ pain

— Sexual dysfunction, urinary retention

— Sedation, hypotension, bradycardia, rebound hypertension on abrupt discontinuation (always taper)

— Stimulants + MAOI = hypertensive crisis

— Atomoxetine + paroxetine/fluoxetine → 2-3× drug levels

Key distinction: Stimulant misuse (taking more than prescribed, snorting) ≠ diversion (giving/selling to others). Both warrant clinical action but differ in severity and management.

Board pearl: Worsening anxiety, irritability, or insomnia after starting a stimulant should prompt dose reduction or switch — not adding a benzodiazepine.

Untreated ADHD complications:

Stimulant-related adverse effects:

Atomoxetine adverse effects:

α2-agonist adverse effects:

Drug interactions of note:

When to Escalate Care and Consult Specialty

— Comorbid bipolar disorder, psychosis, severe MDD, or active suicidality

— Failure of two stimulant trials and one non-stimulant trial

— Diagnostic uncertainty (e.g., autism spectrum, personality disorder, dissociation)

— Patient on complex psychotropic regimen

— Substance use disorder requiring integrated treatment

— Baseline ECG abnormality (LVH, QTc prolongation, conduction disease)

— Family history of sudden cardiac death <40 or HCM

— Symptoms suggesting structural heart disease

— New chest pain, syncope, palpitations on stimulant therapy → hold stimulant pending evaluation

— Positive OSA screen, suspected narcolepsy, severe delayed sleep phase

— Treating OSA may resolve apparent "inattention" entirely

— Co-occurring learning disability or TBI suspected

— Documentation needed for academic/workplace accommodations

— Cognitive decline of unclear etiology

— Stimulant-induced psychosis or mania → hold medication, urgent psychiatry, consider hospitalization

— Hypertensive urgency on stimulant → hold, evaluate for secondary HTN, switch class

— Suicidal ideation with plan → ED evaluation

— Suspected overdose: agitation, hyperthermia, tachycardia, hypertension → ED, benzodiazepines for agitation, supportive care, avoid β-blockers alone (unopposed α-agonism)

— Communicate with PCP, OB (if relevant), and any other prescriber

— Use a single pharmacy and reconcile PDMP at every refill

CCS pearl: A patient on lisdexamfetamine presenting with new chest pain — the correct order set is hold stimulant, ECG, troponin, BP, cardiology consult. Do not simply continue and "monitor."

Step 3 management: Document escalation thresholds at treatment initiation so future providers know when to act.

Routine outpatient management is appropriate for the majority of uncomplicated adult ADHD.

Refer to psychiatry when:

Refer to cardiology when:

Refer to sleep medicine when:

Refer for neuropsychological testing when:

Emergency/acute escalation:

Care coordination essentials:

Key Differentials — Other Psychiatric Causes

— Impaired concentration is episodic, accompanied by anhedonia, sleep/appetite changes, guilt, fatigue

— Pre-pubertal onset uncommon; mood episode duration ≥2 weeks

— Treat depression first; reassess attention after remission

— Worry-driven distractibility, restlessness from internal tension

— Somatic symptoms (muscle tension, GI), sleep onset insomnia from rumination

— Anxiety and ADHD coexist frequently; treat both, but if anxiety is primary, SSRI ± CBT first

— Distractibility during discrete manic/hypomanic episodes with elevated mood, decreased sleep need, grandiosity

— Mood episodes are time-limited (≥4 days hypomania, ≥7 days mania)

— Must rule out before stimulants — screen with MDQ

— Hypervigilance, concentration impairment, irritability, sleep disturbance

— Trauma history with re-experiencing, avoidance, negative cognitions

— Onset tied to trauma rather than childhood

— Social communication deficits, restricted/repetitive behaviors

— Attention is selective and intense within special interests (overlap with hyperfocus)

— Co-occurs with ADHD in ~30-50% — treat both

— Affective instability triggered by interpersonal stress, identity disturbance, fear of abandonment, parasuicidal behavior

— Impulsivity is interpersonally driven

— DBT is first-line, not stimulants

— Cocaine, amphetamine, cannabis intoxication/withdrawal can mimic both inattention and hyperactivity

— Always obtain UDS at evaluation

— Disorganized thought, psychotic features, negative symptoms with cognitive impairment

Key distinction: Episodicity is the single most useful differentiator. ADHD is lifelong and trait-like; MDD, bipolar, PTSD, and SUD-related cognitive symptoms are episodic or onset-tied.

Board pearl: When a vignette gives both childhood onset AND clear episodic mood symptoms, the diagnosis is comorbid — and bipolar must be stabilized first.

Major depressive disorder:

Generalized anxiety disorder:

Bipolar disorder:

PTSD:

Autism spectrum disorder:

Borderline personality disorder:

Substance use disorders:

Schizophrenia/schizoaffective disorder:

Key Differentials — Medical and Sleep Causes

— Daytime sleepiness, morning headaches, witnessed apneas, BMI >30, neck circumference >17 in men/16 in women

— STOP-BANG or Epworth Sleepiness Scale → polysomnography

— Treating OSA with CPAP can resolve "inattention" entirely

— Hyperthyroidism: restlessness, tachycardia, tremor, weight loss, heat intolerance — mimics hyperactive ADHD

— Hypothyroidism: fatigue, cognitive slowing, weight gain — mimics inattentive ADHD

— Order TSH at baseline when suggestive

— Fatigue, poor concentration; restless legs syndrome can disrupt sleep and mimic ADHD

— CBC, ferritin

— B12 deficiency: cognitive impairment, neuropathy, macrocytosis

— Folate, vitamin D — limited but worth checking when clinically suggestive

— Traumatic brain injury — even mild concussions can produce ADHD-like sequelae (post-concussive cognitive dysfunction)

— Absence seizures — staring spells in childhood; obtain EEG if suspected

— Early-onset dementia (frontotemporal in particular) — executive dysfunction, disinhibition, lack of insight

— Multiple sclerosis — cognitive symptoms can be prominent

— Anticholinergics, benzodiazepines, opioids, sedating antihistamines, anticonvulsants (topiramate)

— Review medication list at evaluation

— Chronic cannabis use — amotivation, memory impairment

— Alcohol use disorder — cognitive impairment, withdrawal anxiety

— Stimulant withdrawal — fatigue, depression, hypersomnia

— Cushing's, hypoglycemia, hypercalcemia — rarely the answer but appear as distractors

Board pearl: A 45-year-old male, BMI 36, snoring, hypertensive, with "concentration problems" should get a sleep study before any ADHD evaluation. Untreated OSA is the most commonly missed mimic on Step 3.

Key distinction: Medical mimics typically lack the childhood onset anchor — return to the developmental history when uncertain.

Step 3 management: A targeted "ADHD mimic panel" — TSH, CBC, ferritin, B12, UDS, sleep screen, medication reconciliation — costs little and protects against misdiagnosis.

Obstructive sleep apnea:

Thyroid disease:

Anemia and iron deficiency:

Vitamin deficiencies:

Neurologic conditions:

Medication-induced cognitive impairment:

Substance use and withdrawal:

Endocrine/metabolic:

Long-Term Management and Continuity of Care

— ADHD is chronic; treat as long as functional benefit outweighs risks

— Periodic re-evaluation of need (annual minimum), not automatic discontinuation

— "Drug holidays" not routinely recommended in adults; may be considered for appetite/growth in adolescents

— Tolerance to therapeutic effect is uncommon; apparent "tolerance" usually reflects increased life demands, sleep deprivation, or psychiatric comorbidity

— Avoid escalating dose without reassessing comorbidity, sleep, and substance use

— Single prescriber, single pharmacy

— No early refills, no replacement for lost/stolen prescriptions without police report

— PDMP review at every visit

— Urine drug screen as clinically indicated

— Consequences of misuse, diversion, or non-adherence

— Schedule II (most stimulants): no refills, paper or compliant e-prescription, max 30-day supply in most states; some states permit 90-day with sequential dating

— Schedule IV: atomoxetine, viloxazine, bupropion are not controlled

— BP and HR at every visit

— Repeat ECG if symptoms develop or with significant dose escalation

— Screen for depression (PHQ-9), anxiety (GAD-7), mania (MDQ), SUD (AUDIT-C, DAST) annually

— Repeat ASRS or AISRS every 3-6 months

— Track work/school performance, relationship stability, driving record

— Regular exercise (aerobic, 150 min/week) — small but real benefit on attention

— Sleep hygiene, consistent schedule

— Limit alcohol and cannabis

— Mediterranean-style diet; omega-3 has weak evidence

Step 3 management: At each refill, do a 5-element check: ASRS, BP/HR, PDMP, side-effect inventory, comorbidity screen. This is the outpatient equivalent of a discharge med rec and is the rhythm tested on Step 3.

Board pearl: Spontaneous symptom worsening after years of stable response → look for new sleep deprivation, alcohol use, depression, or thyroid disease before increasing the dose.

Treatment duration:

Medication adjustments over time:

Stimulant treatment agreement components:

Controlled substance regulations:

Cardiovascular monitoring:

Mental health monitoring:

Functional outcome tracking:

Lifestyle adjuncts:

Follow-Up Cadence, Monitoring, and Counseling

— Initiation: visit at 2-4 weeks for response, tolerability, BP/HR, side effects

— Titration: every 1-2 weeks until optimal dose

— Maintenance: every 3 months for the first year, then every 6 months once stable

— Annual comprehensive review: comorbidity rescreen, ECG if indicated, lab review, functional assessment

— Symptom rating scale (ASRS or AISRS)

— BP, HR, weight, BMI

— Adverse effects (sleep, appetite, mood, libido)

— Adherence and pill count if concerning

— PDMP query

— Substance use screen

— Driving safety, work/school performance

— Take stimulant in the morning to minimize insomnia; avoid late-afternoon dosing

— Eat protein-containing breakfast before dosing (offsets appetite suppression later)

— Hydration, especially with exercise

— Avoid combining with cold medications containing pseudoephedrine

— Alcohol does not interact pharmacokinetically but worsens cognitive symptoms and impairs adherence

— Driving: stimulants improve driving performance in ADHD — but do not drive during washout/rebound periods

— 8-12 sessions of CBT adapted for ADHD: organization, time management, problem-solving, cognitive restructuring of negative self-narratives

— Use of calendars, reminder apps, body-doubling, externalized structure

— ADA: extended deadlines, written instructions, quiet workspace, frequent breaks

— Document diagnosis for HR or disability services

— Psychoeducation for partners reduces relationship conflict

— Address comorbid family-of-origin ADHD when present

Board pearl: The 2-4 week early follow-up after stimulant initiation is the most commonly tested follow-up interval on Step 3.

Step 3 management: Schedule the next refill visit before the patient leaves; gaps in care drive ED visits and treatment discontinuation.

Follow-up schedule:

At every visit, document:

Patient counseling points:

CBT and coaching adjuncts:

Workplace and academic accommodations:

Family involvement:

Ethical, Legal, and Patient Safety Considerations

— Explicit discussion and documentation of stimulant risks: CV effects, misuse potential, dependence, psychiatric effects, driving impact, pregnancy considerations

— Document the patient's understanding and agreement

— Use a written treatment agreement signed by patient and prescriber

— Up to 20% of college students with stimulant prescriptions divert

— Strategies: long-acting formulations (especially lisdexamfetamine), single-pharmacy rule, PDMP at every refill, urine drug screen as clinically indicated, no early refills

— Suspected diversion → not automatic discharge; discuss, document, switch to non-stimulant or lisdexamfetamine, taper if pattern continues

— Red flags: requesting specific brand/dose, prior providers "wouldn't prescribe," normal childhood school records, symptom report inconsistent with collateral

— Use objective measures (ASRS, collateral history, records) — do not rely on patient self-report alone

— Decline to prescribe when criteria are not met; document reasoning

— Patients with active ADHD have impaired driving — counsel on treatment adherence, avoid driving during washout/rebound

— Commercial drivers, pilots (FAA), and military personnel face occupational restrictions on stimulants — atomoxetine or non-stimulant alternatives often required

— Suspected child or elder abuse linked to impulsivity-driven neglect must be reported per state law

— Impaired driving causing injury may trigger reporting in some states

— Pediatric-to-adult handoff is a major safety gap — provide written summary, warm handoff

— College students moving home/away: arrange continuity before semester transitions

— Discontinuation at hospital admission (e.g., surgery): inpatient teams often hold stimulants; ensure outpatient reinstatement plan

— Adult ADHD is underdiagnosed in women, Black, Hispanic, and lower-SES populations

— Bias screening: use structured tools, not gestalt

Board pearl: A patient requesting a stimulant refill while traveling, claiming "lost prescription" — verify PDMP, do not provide early refill without documentation, offer bridging non-stimulant or scheduled visit.

Step 3 management: Document informed consent and treatment agreement at initiation; this is the medicolegal anchor.

Informed consent for controlled substances:

Diversion and misuse:

Malingering for stimulant prescriptions:

Driving and occupational safety:

Mandatory reporting:

Transitions of care:

Equity considerations:

High-Yield Associations and Rapid-Fire Facts

Board pearl: If a question lists childhood symptom onset + adult impairment + normal physical exam + negative TSH + negative MDQ → answer is methylphenidate or lisdexamfetamine, not "obtain neuropsychological testing."

Heritability: ~75% — one of the most heritable psychiatric conditions

Comorbidity rate: 70-80% of adults with ADHD have at least one comorbid psychiatric disorder

Persistence into adulthood: ~60% of childhood ADHD persists in some form

MVC risk: ADHD doubles the risk; treatment reduces it substantially

Substance use: ADHD increases SUD risk; treating ADHD reduces SUD risk (counterintuitive but well-supported)

First-line treatment: Stimulant + CBT

Best initial screening tool: ASRS v1.1

Pre-age-12 onset: DSM-5-TR diagnostic anchor (changed from age 7 in DSM-IV)

Stimulant of choice in SUD risk: Lisdexamfetamine (prodrug, tamper-resistant)

Non-stimulant of choice in SUD: Atomoxetine

MAOI + stimulant: Hypertensive crisis — 14-day washout required

ECG before stimulant: Selective, not universal — only if cardiac history, FHx of SCD, or exam findings

MDQ before stimulant: Always screen for bipolar disorder

Stimulant effect size: ~0.8-1.0 (large); non-stimulant ~0.4-0.7 (moderate)

Atomoxetine onset: 2-6 weeks (not same-day)

Atomoxetine in CYP2D6 poor metabolizers: Reduce dose 50%

Guanfacine/clonidine: Adjunctive; do not abruptly stop (rebound HTN)

Bupropion: Off-label option, especially with depression or tobacco use

Pregnancy: Methylphenidate has the most reassuring data

OSA: Most commonly missed mimic

Hyperfocus: Supports ADHD diagnosis (dysregulated attention, not absent attention)

Mortality: Untreated ADHD has ~2× all-cause mortality (Danish cohort)

Suicide risk: Elevated independent of comorbid MDD

CV monitoring: BP, HR at every visit

PDMP: Check at every refill

Schedule II: Most stimulants; no refills, 30-day max in most states

Atomoxetine and bupropion: Black box for suicidality in young adults

Single-pharmacy rule: Standard of care for stimulant prescribing

Functional outcome > symptom score as treatment goal

Diversion ≠ misuse: Different clinical actions

Board Question Stem Patterns

— 28-year-old new associate at a law firm, chronic procrastination, multiple parking tickets, childhood teacher reports "doesn't apply herself," normal TSH and CBC, PHQ-9 = 4, GAD-7 = 5, MDQ negative

— Answer: ADHD, combined presentation; start long-acting stimulant

— Adult with new "concentration problems" age 35, no childhood history of academic difficulty, recent job stress, PHQ-9 = 18

— Answer: Major depressive disorder; treat MDD first, reassess attention after remission

— 45-year-old male, BMI 38, daytime sleepiness, snoring, hypertensive, "can't focus at work"

— Answer: Sleep study (polysomnography), not stimulant

— 24-year-old with childhood ADHD diagnosis, now with 6-day episode of decreased sleep need, grandiosity, hypersexuality

— Answer: Stabilize bipolar disorder (mood stabilizer) before treating ADHD

— 32-year-old with ADHD and active alcohol use disorder

— Answer: Atomoxetine + SUD treatment; or lisdexamfetamine with monitoring; avoid IR amphetamines

— Adult with ADHD plus exertional syncope and a murmur increasing with Valsalva

— Answer: Echocardiogram (HCM) before any stimulant

— Patient on linezolid develops hypertensive crisis after taking lisdexamfetamine

— Answer: MAOI interaction; discontinue stimulant, supportive care, no β-blocker alone

— College student requests early refill citing lost pills

— Answer: PDMP review, decline early refill, switch to lisdexamfetamine, reinforce treatment agreement

— Patient with ADHD planning pregnancy on amphetamine

— Answer: Multidisciplinary discussion; consider switch to methylphenidate or taper if mild

— Adult on adequate methylphenidate dose × 6 weeks with minimal response

— Answer: Switch to amphetamine class before declaring stimulant failure

Key distinction: Stems test sequencing — stabilize bipolar/SUD/MDD before treating ADHD, evaluate OSA before stimulant, and document childhood onset before diagnosing.

Board pearl: The most-missed answer choice is "obtain sleep study" in any vignette pairing obesity, snoring, and inattention.

Classic Stem 1 — Diagnosis confirmation:

Stem 2 — Diagnostic anchor:

Stem 3 — Mimic detection:

Stem 4 — Bipolar trap:

Stem 5 — SUD comorbidity:

Stem 6 — Pre-stimulant cardiac:

Stem 7 — Drug interaction:

Stem 8 — Diversion management:

Stem 9 — Pregnancy:

Stem 10 — Stimulant non-response:

One-Line Recap

Adult ADHD is a chronic, highly heritable disorder with pre-age-12 symptom onset that is diagnosed clinically using DSM-5-TR criteria, screened for comorbidities (especially bipolar disorder, SUD, anxiety, depression, and OSA) before pharmacotherapy, and treated first-line with long-acting stimulants plus CBT — with atomoxetine or viloxazine reserved for substance use disorder, anxiety, tics, or patient preference — all under structured controlled-substance monitoring with BP, HR, and PDMP at every visit.

Board pearl: When in doubt, return to the pre-age-12 onset anchor — it protects you from misdiagnosing depression, OSA, bipolar disorder, dementia, and substance-induced cognitive impairment as ADHD, and it is the single most tested diagnostic feature on Step 3.

Step 3 management: Untreated ADHD increases mortality, MVC risk, SUD risk, and suicide risk — treating it is a high-value, evidence-based, longitudinal outpatient intervention that fits the Step 3 ambulatory voice perfectly.

Diagnostic anchor: Several symptoms before age 12, ≥5 in inattention and/or hyperactivity-impulsivity, impairment in ≥2 settings, not better explained by another disorder; ASRS supports but does not replace the interview.

Pre-stimulant workup: TSH, sleep screen, MDQ, SUD screen, BP/HR, baseline weight; ECG only if cardiac history or family history of sudden cardiac death; pregnancy testing in patients of childbearing potential.

First-line pharmacotherapy: Long-acting methylphenidate or amphetamine (lisdexamfetamine preferred if diversion risk); atomoxetine first-line if active SUD, prominent anxiety, tic disorder, or patient/occupational preference; combine with CBT for best functional outcomes.

Safety and monitoring: Treatment agreement, single pharmacy, PDMP at every refill, BP/HR/weight/ASRS at every visit, annual comorbidity rescreen, 2-4 week post-initiation follow-up, avoid MAOIs, taper α2-agonists to avoid rebound hypertension.